Dutasteride Associated With Metabolic Safety Concerns

Share this content:
Dutasteride Associated With Metabolic Safety Concerns
Dutasteride Associated With Metabolic Safety Concerns

FRIDAY, June 30, 2017 (HealthDay News) -- Dutasteride for the treatment of benign prostatic hyperplasia may induce imbalance in metabolic function, according to a study published online June 21 in Hormone Molecular Biology and Clinical Investigation.

Abdulmaged Traish, Ph.D., professor of urology with the Boston University School of Medicine, and colleagues reviewed records of 460 men treated at a single urologist's office in Germany for benign prostatic hyperplasia. Half of the men had been prescribed dutasteride (Avodart), and the other half had been prescribed tamsulosin (Flomax). The researchers tracked all of the men for 36 to 42 months, performing blood tests and assessing prostate size and function.

The researchers found that dutasteride was linked to an ongoing rise in hemoglobin A1c among men who received the drug, while men taking tamsulosin did not experience any such increase. Further, long-term dutasteride treatment was linked to increased low-density lipoprotein (LDL) cholesterol levels in men. Men on tamsulosin experienced a smaller but significant increase in their LDL cholesterol levels, but also had an increase in their high-density lipoprotein cholesterol levels.

"Dutasteride therapy also worsened erectile dysfunction and resulted in reduction in testosterone levels. These findings raise serious safety concerns regarding metabolic dysfunction and adverse sexual side effects of long-term dutasteride therapy," the authors write. "Clinicians are strongly urged to discuss these potential health adverse effects of dutasteride treatment with their patients prior to instituting this form of therapy."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »